A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3996401 Following Single and Multiple Ascending Doses of GSK4347859 in Healthy Participants
Latest Information Update: 25 Apr 2025
At a glance
- Drugs GSK 3996401 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors GSK
Most Recent Events
- 22 Apr 2025 Planned number of patients changed from 44 to 65.
- 22 Apr 2025 Planned End Date changed from 13 Apr 2026 to 19 Mar 2026.
- 22 Apr 2025 Planned primary completion date changed from 13 Apr 2026 to 19 Mar 2026.